A Two-part Phase IIb Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Ewing's Sarcoma
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- John Nemunaitis, MD
Gradalis, Inc.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Arkansas Children'S Hospital
Little Rock, Arkansas, United States
- Nicklaus Children'S Hospital (miami Children'S Health System)
Miami, Florida, United States
- Memorial Sloan Kettering Cancer Center
New York, New York, United States
- Cleveland Clinic Children'S
Cleveland, Ohio, United States
- Mary Crowley Cancer Research Centers
Dallas, Texas, United States
- Topa - Medical City Dallas Pediatric Hematology-Oncology
Dallas, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 10 Feb 2016
- Primary completion
- 12 Nov 2018
- Completion
- 23 Dec 2020
- Last update posted
- 22 Dec 2022
- Registered enrollment
- 22
- Registry id
- NCT02511132
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.